Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Mesoblast International Sarl has 3 pending office actions in Biotechnology & Pharmaceuticals. Those matters involve 3 distinct examiners and 2 distinct art units, so examiner responsibility is fully distributed even though the technical assignments are more concentrated.
REGLAS, GILLIAN CHELSEA is the busiest examiner, with 1 pending matter. The absence of a dominant examiner means that counsel should emphasize consistent portfolio positions without assuming that one prosecution history will control the others. Separate analysis of claim language, written-description support, and cited references remains appropriate.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REGLAS, GILLIAN CHELSEA | 1 | 32.3% | +37.5% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.2% | +38.9% |
| PENNINGTON, KATIE LEIGH | 1 | 31.8% | +58.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19028991 | METHOD FOR TREATING OR PREVENTING GASTROINTESTINAL BLEEDING | REGLAS, GILLIAN CHELSEA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19028991 | METHOD FOR TREATING OR PREVENTING GASTROINTESTINAL BLEEDING | REGLAS, GILLIAN CHELSEA | — |
| 19001125 | CELL CULTURE METHOD FOR MESENCHYMAL STEM CELLS | PAGUIO FRISING, MICHELLE F | — |
| 18827638 | PREVENTION OF PROGRESSIVE HEART FAILURE | PENNINGTON, KATIE LEIGH | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19028991 | METHOD FOR TREATING OR PREVENTING GASTROINTESTINAL BLEEDING | REGLAS, GILLIAN CHELSEA | 1632 | §102§103§112 | Non-Final OA | — | Pending | Jan 17, 2025 |
| 19001125 | CELL CULTURE METHOD FOR MESENCHYMAL STEM CELLS | PAGUIO FRISING, MICHELLE F | — | §103Other | Non-Final OA | — | Pending | Dec 24, 2024 |
| 18827638 | PREVENTION OF PROGRESSIVE HEART FAILURE | PENNINGTON, KATIE LEIGH | 1634 | §103§112DP | Non-Final OA | — | Pending | Sep 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMesoblast International Sarl has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Gillian Chelsea Reglas has the most, with 1 of Mesoblast International Sarl's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
